What are P2X3 receptor antagonist drugs?

P2X3 receptor antagonist drugs are pharmacologic agents that share a common mechanism (typically targeting P2X3). 0 are currently marketed, with 5 more in clinical development.

P2X3 receptor antagonist

0 marketed 4 in Phase 3 1 in Phase 2

This page covers all P2X3 receptor antagonist drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting P2X3.

Targets

P2X3

Phase 3 pipeline (4)

MR308 · Mundipharma Research GmbH & Co KG · Pain Management
MR308 is a selective antagonist of the P2X3 receptor that reduces pain signaling in sensory neurons.
BLU-5937 · Bellus Health Inc. - a GSK company · Pain Management / Neurology
BLU-5937 is a selective P2X3 receptor antagonist that blocks pain signaling in sensory neurons.
RTX-GRT7039 · Grünenthal GmbH · Pain Management
RTX-GRT7039 is a selective antagonist of the P2X3 receptor that reduces pain signaling by blocking ATP-mediated nociceptive transmission.
3APS · Bellus Health Inc. - a GSK company · Respiratory
3APS is a selective P2X3 receptor antagonist that blocks pain signaling in sensory neurons to reduce chronic cough.

Phase 2 pipeline (1)

GRT9906 · Grünenthal GmbH · Pain management
GRT9906 is a selective antagonist of the P2X3 receptor that reduces pain signal transmission in sensory neurons.